Tumour detectability in 2-dimensional and 3-dimensional positron emission tomography using the set-2400w: A phantom study

Nuclear Medicine Communications

Volumn 22, Issue 3, 2001, Pages 305-314

  Zhang, H ^a   Inoue, T ^a   Alyafei, S ^a   Tian, M ^a   Oriuchi, N ^a   Endo, K ^a  

^a GUNMA UNIVERSITY   (Japan)

Author keywords

2 dimensional PET; 3 dimensional PET; Standardized uptake value; T N ratio; Tumour detectablility

Indexed keywords

ANIMAL EXPERIMENT; ARTICLE; DIAGNOSTIC IMAGING; MUSCLE TUMOR; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; RABBIT; THREE DIMENSIONAL IMAGING; TUMOR DIAGNOSIS;

ANIMALS; FLUORODEOXYGLUCOSE F18; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; NEOPLASMS; NEOPLASMS, MUSCLE TISSUE; PHANTOMS, IMAGING; RABBITS; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0035055687     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/00006231-200103000-00007     Document Type: Review

References (15)

1. Coleman RE. Revealing biochemistry in a single image. J Nucl Med 1995; 36: 32N-33N.
2. Qkada J, Yoshikawa K, Itami M, et al. Positron emission tomography using fluorine l8-fluorodeoxyglucose in malignant lymphoma: a comparison with proliferative activity. J Nucl Med 1992; 33: 325-329.
3. Strauss LG, Clorius JH, Schlag P, et al. Recurrence of colorectal tumors: PET evaluation. Radiology 1989; 170: 329-332.
4. Berberat P, Friess H, Kashiwagi M, Beger HG, Buchler MW. Diagnosis and staging of pancreatic cancer by positron emission tomography. World J Surg 1999; 23: 882-887.
5. Lowe VJ, Kim H, Boyd JH, Eisenbeis JF, Dunphy FR, Fletcher JW. Primary and recurrent early stage laryngeal cancer: preliminary results of 2-[fluorine-l8]-fluoro-2-deoxy-d-glucose PET imaging. Radiology 1999; 212: 799-802.
6. Patz EF Jr, Lowe VJ, Hoffman JM, Paine SS, Harris LK, Goodman PC. Persistent or recurrent brochogenic carcinoma: Detection with PET and 2-[F-18]-2-deoxy-d-glucose. Radiology 1994; 191: 379-382.
7. Strauss LG, Conti PS. The application of PET in clinical oncology. J Nucl Med 1991; 32: 623-648.
8. Inoue T, Kim EE, Komaki R, et al. Detecting recurrent or residual lung cancer with FDG-PET. J Nucl Med 1995; 36: 788-793.
9. Thompson CJ, Ranger N, Evans AC, Gjedde A. Validation of simultaneous PET emission and transmission scans. J Nucl Med 1991; 32: 154-160.
10. Yamamoto S, Amano M, Miura S, Iida H, Kanno I. Deadtime correction method using random coincidence for PET. J Nucl Med 1986; 27: 1925-1928.
11. Iida H, Miura S, Kanno I, et al. Design and evaluation of HEADTOME 1V: a whole body positron emission tomography. IEEE Trans Nucl Sci 1989; NS-36: 1006-1010.
12. Zhang H, Alyafei S, Inoue T, et al. Comparison on two-dimensional and three-dimensional imaging characteristics of a whole-body PET scanner. Eur J Nucl Med 1998; 25: 1141.
13. Meikle SR, Bailey DL, Hooper PK, et al. Simultaneous emission and transmission measurement for attenuation correction in whole-body PET. J Nucl Med 1995; 36: 1680-1688.
14. Tanaka G. Japanese Reference Man 1988. Ann Japan Radiol Soc 1988, 48: 509-513.
15. Lowe VJ, Duhaylonsod FG, Patz EF, et al. Pulmonary abnormalities and PET data analysis. A retrospective study. Radiology 1997; 202: 435-439.